AsiDNA

Drug Profile

AsiDNA

Alternative Names: AsiDNA™; Dbait; Dbait32H; DNA bait; DNA repair therapeutic - Onxeo; DSB bait; DT01; DT1

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator DNA Therapeutics
  • Developer Onxeo SA
  • Class Antineoplastics; Gene therapies; Small molecules
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Preclinical Cancer; Solid tumours

Most Recent Events

  • 13 Feb 2017 Onxeo receives patent allowance for AsiDNA™ in USA
  • 29 Nov 2016 Onxeo will receive patent protection for AsiDNA in Europe
  • 07 Sep 2016 Pharmacodynamics data from a preclinical trial in Solid tumour released by Onxeo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top